Agreement builds on PharmaJet’s strategy to be the best-in-class delivery system for novel DNA- and RNA-based vaccines and immunotherapies usin...
NeuralCure AI announced the official launch of its groundbreaking Diagnostic & Digital Twin Operating System, the first infrastructure platform...
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of ...
Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combi...
Expands the collaboration to manufacture two malaria vaccine candidates (R78C and RH5.1) for Phase 1/2 clinical trials. Delivers the sixth m...
diaMentis, a company developing an innovative diagnostic support technology in mental health, recognized by the U.S. Food and Drug Administration (FDA) a...
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for th...
HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...
Largest demonstration of its kind combines leading hardware, platforms, and techniques to achieve 20 times speedup over previous demonstrations Ecosys...
Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule all...
Valneva SE , a specialty vaccine company, announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluatin...
Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, toda...
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated ...
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treat...
© 2025 Biopharma Boardroom. All Rights Reserved.
